Femogesal 0.03 / 0.075 mg 21 tablets

Tradename

Femogesal

Composition

Each tablet contains:

Gestodene 75 mcg

Ethinylestradiol 30 mcg

Auxiliary components:

sodium calcium edetate, lactose monohydrate, corn starch, povidone, magnesium stearate.

Shell composition: sucrose, povidone, polyglycol, calcium carbonate, talc, mountain glycolic wax (montanglycolic wax).

Properties

The combination of gestodene + ethinyl estradiol inhibits the secretion of gonadotropic hormones; inhibits the maturation of follicles; interferes with the ovulation process; reduces the susceptibility of the endometrium to the blastocyst and increases the viscosity of the cervical secretion, making it difficult for sperm to enter the uterine cavity.

In women taking COCs, the cycle becomes more regular, the soreness and intensity of menstrual bleeding decrease, as a result of which one of the risk factors for the development of iron deficiency anemia decreases. Taking COCs with a high content of

ethinyl estradiol (50 mcg) reduces the risk of developing ovarian and endometrial cancer.

Indications

Oral contraception.

Method of administration and dosage:

Femozhesal is taken orally 1 tab. / Day at the same time without gaps for 21 days, followed by a 7-day break before taking the next package.

Contraindications

-increased sensitivity to drug components;

thromboembolism of the arteries at present or in history (myocardial infarction, cerebrovascular disorders);

venous thromboembolism at present or in anamnesis (phlebitis, pulmonary embolism)

Side effects

Often:

-decreased libido, depression, neurosis;

-nausea, abdominal pain;